Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 August 2024
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 December 2024
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 December 2024
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 February 2025
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer ID5110Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer ID6177Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Treatments for non-small-cell lung cancer [ID6234]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [ID6346]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID 6399Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer (Review of TA662) [ID6404]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812Status:Topic selectionProgramme:Health technology evaluationExpected publication date: TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Archimedes for biopsy of suspected lung cancerStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Signatera molecular residual disease assay (MT741)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy, (MT158)Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations TSID 12011Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC